Striking at the heart of antimicrobial resistance, the international NeoSep 1 trial to evaluate life-saving antibiotic combinations for newborns with sepsis has expanded to India, with the first baby being recruited at the Jawaharlal Postgraduate Education Institute of Medical and Research (JIPMER) in Puducherry.

This was followed by recruiting an infant for the study in Pt. B.D. Sharma PGIMS in Rohtak. The next on the list is Lokmanya Tilak Municipal College and General Hospital, Mumbai. Globally, the study, sponsored by the GARDP Foundation in collaboration with the UCL Innovative Clinical Trials Unit; City St George’s, University of London (SGUL), and Penta Foundation, is also underway in Vietnam and Pakistan, and will soon start in Malaysia, Bangladesh and Uganda.

Source

India has enroled its first newborn in a landmark global clinical trial that could reshape how doctors treat one of the biggest killers of infants, neonatal sepsis, at a time when the antibiotics used for decades are rapidly losing their power.

Sepsis in newborns, or neonatal sepsis, is a serious medical condition that occurs when a baby younger than 28 days old has a life-threatening response to an infection.

Source

24 June 2026

When newborns develop sepsis, doctors often have only hours to save them. But increasingly, known antibiotics are failing against drug-resistant bacteria, forcing clinicians to improvise with a bewildering range of alternatives¹.

A major international clinical trial has now begun recruiting newborns in India to address this growing dilemma in neonatal intensive care units. The trial, led by the Global Antibiotic Research and Development Partnership (GARDP), will test and rank multiple antibiotic combinations for neonatal sepsis, one of the leading causes of newborn deaths worldwide.

Source

18 June 2026

GENEVA—Despite delivering extraordinary gains in the fight against child mortality and diseases such as HIV, polio, and malaria, the global health system has come under strain not only from shrinking resources but also from unprecedented scrutiny and rising expectations.

Critics rightly point out that today’s global health architecture is fragmented, costly, and not always responsive to evolving needs. Donor and recipient governments, as well as other funders, are increasingly demanding a more efficient system that reduces duplication, breaks down silos, empowers country leadership, and supports national health systems.

Source

12 June 2026

Three Geneva-based health organisations will join forces to speed up research and development into treatments for malaria, neglected diseases and drug-resistant infections, amid global aid cuts and calls for global health architecture reform.

The Drugs and Neglected Diseases Initiative (DNDi), the Medicines for Malaria Venture (MMV) and the GARDP Foundation, announced plans on Monday to work more closely together as part of efforts to stay ahead of a rapidly shifting environment.

Source

16 April 2026

A landmark clinical trial to evaluate life-saving antibiotic combinations for treating newborns with sepsis has started in Ghana.

The NeoSep1 clinical trial in Ghana began with the first baby recruited at Komfo Anokye Teaching Hospital (KATH) in Kumasi. The trial builds on ongoing work in Africa, where newborns have been enrolled in the trial in hospitals in South Africa and Kenya.

Source

2026年1月20日

研究の背景：薬剤耐性淋菌という世界的脅威

　性感染症を診察したことがなくても、「淋菌」や「クラミジア」なんて病名を耳にしない読者の先生方はいないだろう。これらは、尿道炎や子宮頸管炎を起こす主な細菌で、性感染症の大多数はこれらが原因と考えていただいてもよい。性病の原因菌である淋菌が、とんでもない状況にあることをご存じだろうか？

Source

The Global Antibiotic Research & Development Partnership (GARDP) and Swiss biopharmaceutical company Debiopharm today announced a collaboration on a novel antibiotic targeting gonorrhea.

Under the collaboration and license agreement, GARDP and Debiopharm will jointly develop Debio1453, a first-in-class antibiotic candidate that targets an enzyme that’s essential for the growth of Neisseria gonorrhoeae and has shown potent clinical activity against the bacterium in preclinical studies, including multidrug-resistant strains.

Source

スイスに本部を置く非営利団体のグローバル抗菌薬研究開発パートナーシップ(GARDP)はこのほど、りん病の新たな抗菌薬が米食品医薬品局（FDA）の承認を得たと発表した。世界初となる飲み薬で、りん病の薬が承認されたのは数十年ぶり。りん病は既存の抗菌薬に耐性をもつ耐性菌が広がっており、世界的な課題となっていた。

Source

New antibiotics hailed as ‘turning point’ in treating drug-resistant gonorrhoea

New gonorrhea drug is not just a scientific breakthrough but a business one

FDA Approves First New Gonorrhoea Treatment in Decades Amid Rising Antibiotic Resistance

F.D.A. Approves Two New Drugs to Treat Gonorrhea

FDA approves first new antibiotics to treat gonorrhea in decades, with hope to combat drug resistance

US FDA approves Innoviva’s oral antibiotic for gonorrhea

Pharma major Dr. Reddy’s to produce and market drug for gonorrhoea granted approval by U.S. FDA

New antibiotics for gonorrhea could help beat back drug-resistant infections

New antibiotic could stave off drug-resistant gonorrhoea

FDA approves first new kind of drug to target gonorrhea in decades

With strong phase 3 findings, a new antibiotic for gonorrhea is on the horizon

FDA endorses 2nd new gonorrhea treatment, clearing way for Innoviva’s Nuzolvence

Why the approval of two new gonorrhoea treatments is a game changer

りん病の新たな抗菌薬、数十年ぶりに承認　世界初の飲み薬

Source